Feasibility and safety of tailored dosing schedule for eculizumab based on therapeutic drug monitoring: lessons from…
Eculizumab is an anti-C5 monoclonal antibody approved for rare diseases including atypical haemolytic-uraemic syndrome. The maintenance phase dosing regimen is identical for all adult patients: 1200 mg every 2 weeks.
- Ref: Br J Clin Pharmacol. 2020 Oct 28.
- Année de publication : 2020
- Auteurs : Passot C, Sberro-Soussan R, Bertrand D, Caillard S, Schvartz B, Domenger C, Contin-Bordes C, Paintaud G, Halimi JM, Ternant D, Gatault P. Br
- Réseaux : Réseaux: non classé